Catherine Creuzot‐Garcher

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Arshad M. Khanani, Sunil Patel, Giovanni Staurenghi et al. · The Lancet · 2023 · 263 citations · Full text

Clinical Epidemiology, Clinical Trials, Geographic Atrophy +5

Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

Stefano Bonini, Alessandro Lambìase, Paolo Rama et al. · Ophthalmology · 2018 · 251 citations · Full text

Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term

Christophe Baudouin, P. Hamard, Hong Liang et al. · Ophthalmology · 2004 · 197 citations

Inflammation, Ocular Disease, Ophthalmology +10

The Ocular Surface of Glaucoma Patients Treated over the Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and T-Helper 2 Pathways

Christophe Baudouin, Hong Liang, P. Hamard et al. · Ophthalmology · 2007 · 192 citations

Ocular Disease, Ophthalmology, Immunology +8